

Clinical Trial Protocol

Iranian Registry of Clinical Trials

10 Jun 2026

Evaluation of the increasing effect of gabapentin supplementation on standard (anticholinergic) treatment in controlling stimulus symptoms after double J stent placement in ureteral stone patients

Protocol summary

Study aim

Evaluation of gabapentin supplementation on standard treatment in stimulus symptoms after double J stent in ureteral stone patients

Design

IRCT with control group, with parallel groups, one-way blind, randomized, phase 2 on 150 patients. it's method was Envelope.

Settings and conduct

Study will be performed in the urology department of Imam Reza Hospital. Ureteral stones Patients and TUL treatment with double J catheter, are studied. there are two groups of intervention by random allocation method. First one is treated with anticholinergics and gabapentin 100 and the second is treated with anticholinergics and placebo. 2 weeks later, the results of irritating symptoms are evaluated by using questionnaire (USSQ).

Participants/Inclusion and exclusion criteria

Patients with unilateral ureteral stones with more than 15 mm Having a double J catheter Over 18 years old Chronic use (more than 3 months) of alpha-blocker and analgesic drugs, history of neurogenic bladder, recurrent urinary tract infection or chronic pelvic pain, patient dissatisfaction, discontinuation during study, people who are contraindicated in gabapentin. High risk group due to drug drowsiness

Intervention groups

Intervention group: Administration of anticholinergic drugs and gabapentin 100 1 per day for ureteral stones patients whom double J stent has been used Control group: Prescribing anticholinergic and placebo drugs 1 per day for ureteral stones patients whom double J stent has been used

Main outcome variables

Stimulus symptoms are recorded and evaluated in all studied patients based on a questionnaire 2 weeks after the study.

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20170417033489N8**

Registration date: **2021-07-05, 1400/04/14**

Registration timing: **registered_while_recruiting**

Last update: **2021-07-05, 1400/04/14**

Update count: **0**

Registration date

2021-07-05, 1400/04/14

Registrant information

Name

Salman Soltani

Name of organization / entity

Mashhad University of Medical Sciences

Country

Iran (Islamic Republic of)

Phone

+98 51 3802 2553

Email address

soltanis@mums.ac.ir

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2021-06-22, 1400/04/01

Expected recruitment end date

2023-03-20, 1401/12/29

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Evaluation of the increasing effect of gabapentin supplementation on standard (anticholinergic) treatment in controlling stimulus symptoms after double J stent placement in ureteral stone patients

Public title

The effect of gabapentin supplementation in ureteral stone patients

Purpose

Prevention

Inclusion/Exclusion criteria

Inclusion criteria:

Patients with unilateral ureteral stones more than 15 mm in diameter who have undergone TUL lithotripsy Patients should be over 18 years old A double G catheter is installed for them

Exclusion criteria:

Chronic use (more than 3 months) of alpha-blocker and analgesic drugs History of neurogenic bladder Recurrent urinary tract infections Chronic pelvic pain Patient dissatisfaction Leaving the study during the study process People who are contraindicated in gabapentin History of previous allergy to gabapentin Pregnancy Breastfeeding Liver failure Renal failure People who are in the high-risk group due to the drowsiness complication of the drug

Age

From **18 years** old

Gender

Both

Phase

3

Groups that have been masked

- Participant

Sample size

Target sample size: **76**

Randomization (investigator's opinion)

Randomized

Randomization description

After the visit of each patient with inclusion criteria, an envelope is taken in order and according to the code written in it (for example a / b) the patient is placed in one of two groups

Blinding (investigator's opinion)

Single blinded

Blinding description

After the visit of each patient with inclusion criteria, an envelope is taken in order and according to the code written in it (for example a / b) the patient is placed in one of two groups.

Placebo

Used

Assignment

Parallel

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Mashhad Ethics Committee of the Medical School

Street address

Department of Knowledge & Health, Shahid Fakouri blvd, Mashhad, Khorasan Razavi

City

Mashhad

Province

Razavi Khorasan

Postal code

99191-91778

Approval date

2020-09-30, 1399/07/09

Ethics committee reference number

IR.MUMS.MEDICAL.REC.1399.343

Health conditions studied

1

Description of health condition studied

ureteral stone disease

ICD-10 code

Z96.0

ICD-10 code description

Presence of urogenital implants

Primary outcomes

1

Description

Score obtained based on the patient's irritating symptoms questionnaire

Timepoint

Before intervention and 14 days after gabapentin

Method of measurement

ureteral stent symptom questionnaire (USSQ)

Secondary outcomes

empty

Intervention groups

1

Description

Intervention group: Treated with anticholinergics and gabapentin 100 mg orally once daily. Solifenacin 5 mg orally is used as an anticholinergic drug. After 2 weeks from the start of treatment, the results of improving the irritating symptoms are re-evaluated using the Persian

version of the ureteral stent symptom questionnaire (USSQ). In order to record other information such as patients' personal information, medical records and possible drug side effects during the study (dry mouth, hot flashes, temporary loss of balance, headache, drowsiness, body aches, etc.) from a simple design checklist Will be used by researchers.

Category

Prevention

2**Description**

Control group: Second, they are treated with anticholinergics and placebo with the same prescription as the intervention group. and 5 mg oral sulfinacin is used as an anticholinergic drug.

Category

Placebo

Recruitment centers**1****Recruitment center****Name of recruitment center**

Emam Reza Hospital

Full name of responsible person

Salman Soltani

Street address

Margin of Imam Reza Square, Ibn Sina Blvd, Mashhad.

City

Mashhad

Province

Razavi Khorasan

Postal code

9137913316

Phone

+98 51 3858 3885

Email

soltanis@mums.ac.ir

Sponsors / Funding sources**1****Sponsor****Name of organization / entity**

Mashhad University of Medical Sciences

Full name of responsible person

Dr.Mohsen Taffaghodi

Street address

Department of Knowledge and Health, Fakouri Blvd, Mahhad, Iran

City

Mashhad

Province

Razavi Khorasan

Postal code

99191-91778

Phone

+98 51 3858 3885

Email

soltanis@mums.ac.ir

Grant name**Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

Title of funding source

Mashhad University of Medical Sciences

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin**Type of organization providing the funding**

Academic

Person responsible for general inquiries**Contact****Name of organization / entity**

Mashhad University of Medical Sciences

Full name of responsible person

Dr.Salman Soltani

Position

Assistant Professor

Latest degree

Specialist

Other areas of specialty/work

Urology

Street address

Department of Urology, on the edge of Imam Reza Square, Ibne Sina Blvd, Mashhad.

City

Mashhad

Province

Razavi Khorasan

Postal code

9137913316

Phone

+98 51 3858 3885

Email

soltanis@mums.ac.ir

Person responsible for scientific inquiries**Contact****Name of organization / entity**

Mashhad University of Medical Sciences

Full name of responsible person

Salman Soltani

Position

Assistant Professor

Latest degree

Specialist

Other areas of specialty/work

Urology

Street address

Emam Reza hospital, on the edge of Imam Reza Square, Ibn Sina St, Mashhad

City

Mashhad

Province

Razavi Khorasan

Postal code

9137913316

Phone

+98 51 3858 3885

Email

soltanis@mums.ac.ir

Person responsible for updating data**Contact****Name of organization / entity**

Mashhad University of Medical Sciences

Full name of responsible person

Salman Soltani

Position

Assistant Professor

Latest degree

Specialist

Other areas of specialty/work

Urology

Street address

Department of Urology, Imam Reza hospital, Ibn Sina St, Mashhad

City

Mashhad

Province

Razavi Khorasan

Postal code

9137913316

Phone

+98 51 3858 3885

Email

soltanis@mums.ac.ir

Sharing plan**Deidentified Individual Participant Data Set (IPD)**

Undecided - It is not yet known if there will be a plan to make this available

Study Protocol

Undecided - It is not yet known if there will be a plan to make this available

Statistical Analysis Plan

Undecided - It is not yet known if there will be a plan to make this available

Informed Consent Form

Yes - There is a plan to make this available

Clinical Study Report

Undecided - It is not yet known if there will be a plan to make this available

Analytic Code

Undecided - It is not yet known if there will be a plan to make this available

Data Dictionary

Undecided - It is not yet known if there will be a plan to make this available

Title and more details about the data/document

Only part of the data, such as information about the main outcome, can be shared.

When the data will become available and for how long

Start of the access period three months after the publication of the results

To whom data/document is available

Academic and scientific institutions

Under which criteria data/document could be used

by sending an email

From where data/document is obtainable

by email soltanis@mums.ac.ir

What processes are involved for a request to access data/document

2 months after receiving your request

Comments